- Activist investor Bluebell Capital Partners has built a stake in Bayer AG (OTC:BAYRY) (OTC:BAYZF) and is pushing it to split up.
- The activist has been speaking to Bayer’s supervisory board behind the scenes over the past few months.
- Bluebell has accumulated an undisclosed holding and is seeking an overhaul of Bayer’s corporate governance, Bloomberg reported citing some people familiar with the matter.
- Bluebell has asked Bayer to separate its crop science business from its pharmaceutical unit, which it argues could lead to more than a 70% upside for shareholders, the report added.
- The investor has also been pressurizing Bayer to explore a sale or listing of its consumer-health arm.
- Bayer CEO Werner Baumann has been facing shareholder pressure since the Monsanto deal for $63 billion. The company has set aside an estimated $16 billion to cover lawsuits claiming controversial weedkiller Roundup causes cancer.
- Related: Roundup Weedkiller Maker Bayer Won Five Consecutive Cases, Shifting Momentum In Bayer’s Favor.
- Price Action: BAYRY shares closed at $14.70 on Tuesday.
Dose Escalation Data From TranscendIT-101, Ascendis Pharma’s Phase 1/2 Trial Of TransCon TLR7/8 Agonist In Patients With Advanced Solid Tumors, Presented At SITC 2022
- Early signs of clinical activity were observed in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab; abscopal effect observed with monotherapy
- With a single
